Pioglitazone plus glimepiride: A promising alternative in metabolic control

International Journal of Clinical Practice

Volumn 61, Issue SUPPL. 153, 2007, Pages 28-36

  Derosa, G ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DUETACT; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; LIPID; METFORMIN; PIOGLITAZONE; PIOGLITAZONE PLUS GLIMEPIRIDE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SULFONYLUREA; TROGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE DERIVATIVE; SULFONYLUREA DERIVATIVE;

ADD ON THERAPY; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EDEMA; GLYCEMIC CONTROL; HEART FAILURE; HUMAN; INSULIN RESISTANCE; METABOLIC REGULATION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PLEIOTROPY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; BLOOD; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; METABOLISM; PATIENT COMPLIANCE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; PATIENT COMPLIANCE; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 34347238615     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01362.x     Document Type: Review

References (74)

1. Nathan DM, Buse JB, Davidson MB et al., Professional Practice Committee, American Diabetes Association; European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006 49 : 1711 21.
2. UKPDS Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 : 352 : 837 53.
3. UKPDS Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 352 : 854 65.
4. Erdmann E. Diabetes and cardiovascular risk markers. Curr Med Res Opin 2005 21 : S21 8.
5. Khan MA, St. Peter JV, Xue JL. A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. Diabetes Care 2002 25 : 708 11.
6. Goldberg RB, Kendall DM, Deeg MA et al., GLAI Study Investigators. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005 28 : 1547 54.
7. Shinall S, Buse J, Tan M et al. Glycemic and lipid effects of pioglitazone and rosiglitazone in patients naïve to oral antidiabetic medications. Diabetologia 2006 49 : 703 4.
8. Bell DS. Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy. Clin Ther 2004 26 : 1714 27.
9. Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism 2006 55 : S20 7.
10. Mooradian AD. Towards single-tablet therapy for type 2 diabetes mellitus. Rationale and recent developments. Treat Endocrinol 2004 3 : 279 87.
11. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002 19 : 279 84.
12. Mateo JF, Gil-Guillen VF, Mateo E et al. Multifactorial approach and adherence to prescribed oral medications in patients with type 2 diabetes. Int J Clin Pract 2006 60 : 422 8.
13. Takeda Pharmaceuticals North America, Inc. Duetact (Pioglitazone Hydrochloride and Glimepiride) U.S. Package Insert. Lincolnshire, IL : Takeda Pharmaceuticals North America, Inc., 2006.
14. Miyazaki Y, Mahankali A, Matsuda M et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001 24 : 710 9.
15. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002 87 : 2784 91.
16. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002 25 : 517 23.
17. Bajaj M, Suraamornkul S, Pratipanawatr T et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003 52 : 1364 70.
18. Proks P, Reimann F, Green N et al. Sulfonylurea stimulation of insulin secretion. Diabetes 2002 51 : S368 76.
19. Korytkowski M, Thomas A, Reid L et al. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care 2002 25 : 1607 11.
20. Campbell RK. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus. Ann Pharmacother 1998 32 : 1044 52.
21. Clark HE, Matthews DR. The effect of glimepiride on pancreatic β-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus. Horm Metab Res 1996 28 : 445 50.
22. Koshiba K, Nomura M, Nakaya Y et al. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006 53 : 87 94.
23. Fukuen S, Iwaki M, Yasui A et al. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 2005 280 : 23653 9.
24. Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000 108 : S234 42.
25. Takeda Pharmaceuticals America Inc. Actos (Pioglitazone Hydrochloride) Tablets Prescribing Information (Online). http://www.actos.com/ (accessed May 2006).
26. Shukla UA, Chi EM, Lehr KH. Glimepiride pharmacokinetics in obese versus non-obese diabetic patients. Ann Pharmacother 2004 38 : 30 5.
27. Aronoff S, Rosenblatt S, Braithwaite S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000 23 : 1605 11.
28. Scherbaum WA, Göke B German Pioglitazone Study Group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002 34 : 589 95.
29. Herz M, Johns D, Reviriego J et al., for the GLAB study group. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidaemia in oral antihyperglycemic medication-naïve patients with type 2 diabetes mellitus. Clin Ther 2003 25 : 1074 95.
30. Pavo I, Jermendy G, Varkonyi TT et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003 88 : 1637 45.
31. Schernthaner G, Matthews D, Charbonnel B et al. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab 2004 89 : 6068 76.
32. Korytkowski M. Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride. Pharmacotherapy 2004 24 : 606 20.
33. Sonnenberg GE, Garg DC, Weidler DJ et al. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus. Ann Pharmacother 1997 31 : 671 6.
34. Yamanouchi T, Sakai T, Igarashi K et al. Comparison of metabolic effects of pioglitazone, metformin, and glimepiride over 1 year in Japanese patients with newly diagnosed type 2 diabetes. Diabet Med 2005 22 : 980 5.
35. Tan M, Johns D, Gonzalez Galvez G et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, parallel-group trial. Clin Ther 2004 26 : 680 93.
36. Umpierrez G, Issa M, Vlajnic A. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin 2006 22 : 751 9.
37. Tan MH, Johns D, Strand J et al. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Diabet Med 2004 21 : 859 66.
38. Charbonnel B, Schernthaner G, Brunetti P et al. Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 2005 48 : 1093 104.
39. Tan MH, Baksi A, Krahulec B et al. Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 2005 28 : 544 50.
40. Derosa G, Cicero AFG, Gaddi A et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004 26 : 744 54.
41. Kipnes MS, Krosnick A, Rendell MS et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001 111 : 10 7.
42. Hanefeld M, Charbonnel BH, Brunetti P et al. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004 27 : 141 7.
43. Charbonnel B, Scheen A. Combination therapy with pioglitazone and either metformin or sulfonylurea: glycemic results from PROactive (abstract). Diabetes 2006 55 : A478.
44. Comaschi MA, Di Pietro C, Fionda A et al. Efficacy and safety of pioglitazone in addition to SU or met vs. FC with met plus glyburide in T2 diabetes pts (abstract). Diabetes 2006 55 : A473.
45. UKPDS Group. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group. Diabetes Care 1998 21 : 87 92.
46. Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999 28 : 2005 12.
47. Cook MN, Girman CJ, Stein PP et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care 2005 28 : 995 1000.
48. Xiang AH, Peters RK, Kjos SL et al. Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes 2006 55 : 517 22.
49. Xiang AH, Peters RK, Kjos SL et al. Pharmacological treatment of insulin resistance at two different stages in the evolution of type 2 diabetes: impact on glucose tolerance and beta-cell function. J Clin Endocrinol Metab 2004 89 2846 51.
50. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006 368 : 1096 105.
51. Rosenblatt S, Miskin B, Glazer NB et al. the Pioglitazone 026 Study Group. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001 12 : 413 23.
52. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract 2001 7 : 162 9.
53. Derosa G, Cicero AFG, Gaddi A et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005 69 : 5 13.
54. Tan MH, Glazer NB, Johns D et al. Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Curr Med Res Opin 2004 20 : 723 8.
55. Betteridge DJ, Vergés B. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulfonylurea in the treatment of type 2 diabetes. Diabetologia 2005 48 : 2477 81.
56. Derosa G, Cicero AF, D'Angelo A et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006 28 : 679 88.
57. Spanheimer R, Tan M, Yates J on behalf of the PROactive Investigators. The effects of long-term pioglitazone therapy on lipid profiles in high-risk type 2 diabetes patients: results from PROactive. Diabetologia 2006 49 : 69 70.
58. Matsui J, Terauchi Y, Kubota N et al. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet. Diabetes 2004 53 : 2844 54.
59. Zeender E, Maedler K, Bosco D et al. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1beta. J Clin Endocrinol Metab 2004 89 5059 66.
60. Wallace TM, Levy JC, Matthews DR. An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. Diabet Med 2004 21 : 568 76.
61. Haffner SM, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002 106 : 679 84.
62. Marx N, Imhof A, Froehlich J et al. Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease. Circulation 2003 107 : 1954 7.
63. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab 2004 89 : 2728 35.
64. Pfutzner A, Marx N, Lubben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005 45 : 1925 31.
65. Derosa G, Cicero AFG, D'Angelo A et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. Hypertens Res 2005b 28 : 917 24.
66. Forst T, Hohberg C, Fuellert SD et al. Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes. Horm Metab Res 2005 37 : 521 7.
67. Langenfeld MR, Forst T, Hohberg C et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005 111 : 2525 31.
68. Forst T, Lubben G, Hohberg C et al. Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2. Microcirculation 2005 12 : 543 50.
69. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 36 : 1279 89.
70. Derosa G, Franzetti I, Gadaleta G et al. Metabolic variations with oral antidiabetic drugs in patients with type 2 diabetes: comparison between glimepiride and metformin. Diabetes Nutr Metab 2004 17 : 143 50.
71. Diamant M, Schindhelm R, Heine RJ, on behalf of the PROactive Investigators. Long-term treatment with pioglitazone improves markers of liver function in patients with type 2 diabetes: results from PROactive. Diabetologia 2006 49 : 72 3.
72. Berlie HD, Kalus JS, Jaber LA. Thiazolidinediones and the risk of edema: a meta-analysis. Diabetes Res Clin Pract 2007 76 : 279 89.
73. Basu A, Jensen MD, McCann F et al. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006 29 : 510 4.
74. Derosa G, D'Angelo A, Ragonesi PD et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006 31 : 375 83.